Channel
@clinical_trials
On this record: Growth · Engagement · Reactions · Posts · Telegram's recommendations · Cite this entry
998subscribers
+8 since we began measuring on 16 September 2026
Risers and fallers across the register · movement among entries of Under 1,000.
| Telegram ID | -1001549705298 |
|---|---|
| Type | Channel |
| Username | @clinical_trials |
| Created | Between 1 August 2021 and 28 February 2023 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 16 September 2026 |
| Last confirmed live | 18 September 2026 |
| Measurements held | 3 |
| Confirmed unchanged | 1 time, most recently 18 September 2026 |
| On Telegram | t.me/clinical_trials |
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 18 Sept 2026, 16:16 | 998 | +8 |
| 16 Sept 2026, 14:22 | 990 | no change |
| 16 Sept 2026, 13:47 | 990 | first reading |
20 posts held, back to 8 September 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate. It is computed over the 1 of 20 measured posts that carry a reaction reading, and over those same posts' views.
| Window | Rolling 30 days · latest post in window 16 September 2026 |
|---|---|
| Posts held | 20 (8 September 2026 – 16 September 2026) |
| Views total | 668 |
| Reactions total | 1 |
| Forwards / comments | not exposed by the public surface — not measured, not estimated |
| Readings taken | 16 Sept 2026, 14:22 UTC |
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
1 reaction across 1 post, in 1 kind.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 1 | 100.0% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 1 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 1 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 20 most recent posts we hold, published 8 September 2026 to 16 September 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
From 7,000 drugs to one active against resistant strains: AI advances pneumonia drug repurposing Streptococcus pneumoniae is a bacterial pathogen that causes life-threatening infections, including pneumonia and meningitis. These infections are commonly treated with antibiotics, but antibiotics are becoming less effective against S. pneumoniae over time because of changes in the pathogen that cause drug resistance. T…
❤1
Drug improves sexual function for patients with depression, study finds Patients with major depressive disorder (MDD) and an inadequate response to standard antidepressants who received add-on treatment with the drug lumateperone had significantly improved sexual function, according to a new study led by a University of Virginia School of Medicine researcher. https://medicalxpress.com/news/2026-09-drug-sexual-funct…
Experimental drug shows potential for hard-to-treat heart disease An experimental drug has been shown to improve symptoms, exercise capacity and heart failure status in patients with an inherited heart disease, according to a pair of newly published studies. https://medicalxpress.com/news/2026-09-experimental-drug-potential-hard-heart.html
Common epilepsy drug levetiracetam presents potential clot risk for patients taking blood thinners Researchers from the University of Liverpool and the University of Zurich have identified a potential safety consideration involving levetiracetam, one of the world's most commonly prescribed antiseizure medications. https://medicalxpress.com/news/2026-09-common-epilepsy-drug-levetiracetam-potential.html
Common antibiotic linked to possible higher death risk Cefepime is a fourth-generation antibiotic widely used to treat serious bacterial infections and febrile neutropenia—a fever in patients with abnormally low white blood cell counts. Unlike many antibiotics that are falling prey to antimicrobial resistance, cefepime is relatively stable against AmpC β-lactamases, giving it an advantage against bacteria that produ…
New US Medicare pricing policies could reshape global pharmaceutical markets A new modeling study published in The Lancet suggests that U.S. Medicare's new "Most-Favored-Nation" pricing policy, which ties what Medicare pays for medicines to prices charged in other high-income countries, could push pharmaceutical manufacturers to raise prices or delay launches. For about three in four medicines studied, the resulting…
Masked antibodies may open intracellular treatment route for Parkinson's disease Over the past few decades, antibody-based therapies have revolutionized modern medicine and are now widely used to treat cancer, autoimmune diseases, inflammatory disorders and even infectious diseases. Despite their success, however, antibodies have a significant limitation: They struggle to penetrate cells and are therefore largely li…
AI virtual cell uses protein dynamics to predict personalized breast cancer treatments Not all cancer cells are the same, and neither are their responses to drugs. Finding the right drug for the right cancer cell is a long battle in drug development and in designing effective treatments. A new AI tool called ProteinTalks makes this task easier by accurately predicting whether a drug will be effective against a cance…
Promising broad-spectrum antiviral candidate against enteroviruses identified Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have identified a promising antiviral compound that can inhibit a range of enteroviruses, including Enterovirus D68 (EV-D68), an emerging respiratory virus linked to severe respiratory illness and acute flaccid myelitis, a condition that …
Chemotherapy alters 'Darwinian battleground' in our bodies Cancer treatments, including chemotherapy and radiation therapy, give a growth advantage to cells with particular genetic changes in healthy tissue, new research finds. https://medicalxpress.com/news/2026-09-chemotherapy-darwinian-battleground-bodies.html
Potentially harmful drug combinations prescribed to older adults identified A new Ontario-wide study reveals that common medications, from statins to iron supplements, are quietly setting off prescribing cascades that leave older adults unknowingly taking drugs to treat side effects of other drugs. https://medicalxpress.com/news/2026-09-potentially-drug-combinations-older-adults.html
Blood protein analysis suggests a lung disease drug could be fighting aging at the same time In 2025, Insilico Medicine developed an experimental drug called rentosertib as a treatment for idiopathic pulmonary fibrosis, a severe age-related lung disease. The drug works by inhibiting the protein TNIK, which is involved in both scar tissue formation in the lungs and fundamental hallmarks of biological aging. The resea…
Showing the 12 most recent of 20 posts we hold for @clinical_trials. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.
This channel appears in 2 seed channels' Telegram-generated recommendation lists in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 18 September 2026 — this entry's latest reading, not the date you are reading this.
“Clinical Trials | Medications” (@clinical_trials), 998 subscribers as measured 18 September 2026. Telegram Register, tgregister.com/channel/clinical_trials.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.